Law firm says Aardvark investors may seek lead plaintiff in securities case

By Atlas Watchline Staff · Legal · August 28, 2026

A law firm says Aardvark Therapeutics investors with losses may seek lead-plaintiff status in a securities fraud class action before an Oct. 13, 2026 deadline.

A law firm says investors who lost money in Aardvark Therapeutics, Inc. may seek to lead an ongoing securities fraud class action. The lead-plaintiff deadline is Oct. 13, 2026.

The Law Offices of Howard G. Smith said in a PR Newswire release dated Aug. 28, 2026, in Bensalem, Pennsylvania, that investors with substantial losses in Aardvark Therapeutics should contact the firm before the deadline if they want to seek lead-plaintiff status. The release identifies the company by ticker AARD.

What the release says

According to the press release, the complaint covers a class period from Feb. 10, 2025, through May 14, 2026. It says the complaint alleges defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Aardvark Therapeutics’ business, operations and prospects.

The release summarizes three allegations. It says the complaint alleges ARD-101 was less safe than investors were led to believe, that ARD-101’s clinical, regulatory and commercial prospects were overstated, and that public statements were materially false and misleading during the relevant period.

What it means for investors

The press release says class members do not need to take action now. It also says investors may retain counsel of their choice or remain absent class members if they do nothing.

Because the notice comes from a law-firm press release, it reflects allegations in a filed complaint and not findings of wrongdoing. The release also says the notice may be considered attorney advertising in some jurisdictions.

Background and contact details

The release lists contact details for the Law Offices of Howard G. Smith, including phone number (215) 638-4847, email [email protected], and the address 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020.

The release does not include a response from Aardvark Therapeutics.

What happens next

Investors who believe they were affected by the alleged conduct can seek more information before the Oct. 13 deadline. The press release says the case remains ongoing.

Sources

• PR Newswire release from the Law Offices of Howard G. Smith

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.